test

A Phase III, Double Blind, Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Conditions

Colon

What is the purpose of this trial?

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer.


Participation Guidelines

Age:
Gender:

Click here for detailed information about who can participate in this trial.


Sponsor:
Southwest Oncology Group (SWOG)
Dates:
05/16/2014
Last Updated:
Study HIC#:
1402013375